Internal medicine

Pathology

Placebo

Letrozole

Cancer

Oncology

Metastatic breast cancer

Alternative medicine

Tamoxifen

Oestrogen receptor

Gynecology

Palbociclib

Breast cancer

Human Epidermal Growth Factor Receptor 2

Postmenopausal women

Medicine

Estrogen receptor

European Journal of Cancer

The cyclin-dependent kinase 4/6 inhibitor palbociclib has demonstrated efficacy and a manageable safety profile in combination with endocrine therapy in women with oestrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) in international phase 3 trials. The phase 3 PALOMA-4 trial evaluated the efficacy and safety of palbociclib plus letrozole versus placebo plus letrozole in Asian women with ER+/HER2– ABC.

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4